Article
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
AIDS (London, England) - 12 Nov 2007
Marcelin Anne-Geneviève, Jarrousse Bernard, Derache Anne, Ba Madina, Dakouo Marie-Léa, Doumbia Alioune, Haidara Ibrahima, Maïga Almoustapha, Carcelain Guislaine, Peytavin Gilles, Katlama Christine, Calvez Vincent
Abstract excerpt
Early failures to stavudine/lamivudine/nevirapine used as a generic fixed-dose combination in Mali showed resistance mutations in 50% of cases (mostly M184V and Y181C). No thymidine analogue mutations were seen, suggesting that most nucleoside reverse transcriptase inhibitors could be used in a second-line regimen. This highlights the importance of the accessibility of HIV-RNA assays for monitoring treated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.